Trial · NCT02436889
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Participants Who Completed and Discontinued the Study | Mirabegron | Completed study | 11 | Participants | |
| The Number of Participants Who Completed and Discontinued the Study | Tolterodine Tartrate | Completed study | 10 | Participants | |
| The Number of Participants Who Completed and Discontinued the Study | Mirabegron | Discontinued Early | 1 | Participants | |
| The Number of Participants Who Completed and Discontinued the Study | Tolterodine Tartrate | Discontinued Early | 1 | Participants | |
| Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks | Mirabegron | 4.70 | 95% Confidence Interval 1.13 to 8.27 | Score on a Scale | |
| Change From Baseline in California Verbal Learning Test (CVLT) Score at 8 Weeks | Tolterodine Tartrate | 1.59 | 95% Confidence Interval -2.20 to 5.37 | Score on a Scale | |
| Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks | Mirabegron | -11.34 | 95% Confidence Interval -15.57 to -7.11 | seconds | |
| Change From Baseline in Trail Making Test, Trail A Score at 8 Weeks | Tolterodine Tartrate | 0.67 | 95% Confidence Interval -3.79 to 5.13 | seconds | |
| Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks | Mirabegron | -0.39 | 95% Confidence Interval -1.03 to 0.25 | score on a scale | |
| Change From Baseline in Short Physical Performance Battery (SPPB) Score at 8 Weeks | Tolterodine Tartrate | 0.24 | 95% Confidence Interval -0.47 to 0.96 | score on a scale | |
| Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks | Mirabegron | -2.04 | 95% Confidence Interval -3.10 to -0.99 | episodes per day | |
| Change From Baseline in Total Urinary Incontinence Frequency Measured by a Voiding Diary at 8 Weeks | Tolterodine Tartrate | -3.91 | 95% Confidence Interval -5.02 to -2.80 | episodes per day | |
| Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks. | Mirabegron | -1.64 | 95% Confidence Interval -2.73 to -0.54 | episodes per day | |
| Change From Baseline in Urge Incontinence Episodes Per Day on a Voiding Diary at 8 Weeks. | Tolterodine Tartrate | -3.74 | 95% Confidence Interval -4.90 to -2.58 | episodes per day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02436889/results